# Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

> **NCT00003500** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 12 (actual)

## Conditions studied

- Non-hodgkins Lymphoma

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003500
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-03-11
- **Primary completion:** 2000-06-16
- **Final completion:** 2000-06-16
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003500, "Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00003500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*